Immunization Newsbriefs
Link to Main Page
About NNiiParentsHealthcare ProfessionalsPolicy MakersPressroomPartners
Resources: Newsbriefs
Read Current Issue Online
Search Newsbriefs Archives
Subscribe to Email Online
Unsubscribe from Email Online

Vaccine Info Database

Search the Site

Send Your Feedbck
Read Current NewsbriefsBack

FDA to Inspect Vaccine Plant
USA Today; 9D
Rubin, Rita


BioPort, the Michigan drug manufacturer that is the sole producer of an anthrax vaccine for the U.S. government, will submit documents to the Food and Drug Administration (FDA) intended to resolve some issues at its plant. The obstacles facing BioPort's inability to deliver the vaccine involve the plant's extensive manufacturing facility renovations made in order to produce the product. The FDA halted anthrax vaccine shipments in November 1999, after an eight-day inspection revealed potential problems at the plant. Problems identified ranged from improper or insufficient hand washing to failure to investigate adverse reactions reportedly associated with the vaccine. Once it receives the new documents, the FDA will review them and then conduct another inspection of BioPort's plant, before deciding whether or not to approve the company's request for a supplemental license, which is required when a drug manufacturing plant makes extensive renovations.

© Copyright National Network for Immunization Information. The information contained in the National Network for Immunization Information Web site should not be used as a substitute for the medical care and advice of your health care provider. There may be variations in treatment that your health care provider may recommend based on individual facts and circumstances.